Covid 19 Brands

Novavax's protein-based COVID-19 vaccine using recombinant nanoparticle technology and Matrix-M adjuvant, FDA emergency use authorized July 13, 2022, with a biologics license application (BLA) approved May 19, 2025, offering a protein subunit alternative to mRNA-based COVID-19 vaccines for adults and adolescents.

Oral antiviral medication for COVID-19 treatment containing nirmatrelvir and ritonavir, developed and marketed by Pfizer Pharmaceuticals.

American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.